Jubilant Pharma ratings unaffected by proposed reorganisation: Fitch
ANI |
Updated: Jul 30, 2021 12:20 IST
Mumbai (Maharashtra) [India], July 30 (ANI): The proposed transfer of Jubilant Pharma Ltd's (JPL's) active pharmaceutical ingredients (API) business to its parent Jubilant Pharmova Ltd (JPHL) will not affect JPL's ratings, says Fitch Ratings.
The reorganisation is unlikely to change assessment of linkages between JPL and JPHL. Thus Fitch will continue to rate JPL based on the parent's consolidated profile which will remain unaffected by the reorganisation.
Fitch expects JPL's financial profile to remain comfortable as the API business's limited earnings contribution will minimise the impact.
JPHL aims to complete the reorganisation over the next year, subject to receipt of certain regulatory and other approvals, including from the lenders.